PARABDRUGS

Parabolic Drugs Limited has informed the Exchange regarding Change in Auditors of the company.

Parabolic Drugs Limited has informed the Exchange that pursuant to the provisions of Regulations 17, 19 and 20 of the IBBI (Insolvency Resolution Process for Corporate Persons) Regulations, 2016, the third meeting of Committee of Creditors ("CoC") of the Corporate Debtor is scheduled to be held on November 29, 2018 inter-alia to consider and approve the following agenda items as per given below Attachments.

The Exchange had sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone limited review report not submitted The response of the Company is attached.

The Exchange has sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone limited review report not submitted The response of the Company is awaited.

Parabolic Drugs Limited has informed the Exchange regarding outcome of second meeting of committee of creditors of Parabolic Drugs Limited

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2018.

Parabolic Drugs Limited has informed the Exchange regarding Resignation of Mr VK Jindal and associates as statutory auditors of the company w.e.f. October 01, 2018.

Parabolic Drugs Limited has informed the Exchange regarding the Notice of second meeting of Committee of Creditors of the Parabolic Drugs Limited "Corporate Debtor''.

PARABDRUGS:The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 19-Oct-2018, regarding " Parabolic Drugs Limited has informed the Exchange that Intimation regarding change of IRP and appointment of RP in the matter of Corporate Insolvency Resolution Process (CIRP) Of Parabolic Drugs Limited.".On basis of above the Company is required to clarify following:1. Any other material information not involving commercial secrets<br>2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as may

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 19-Oct-2018, regarding " Parabolic Drugs Limited has informed the Exchange that Intimation regarding change of IRP and appointment of RP in the matter of Corporate Insolvency Resolution Process (CIRP) Of Parabolic Drugs Limited.". On basis of above the Company is required to clarify following: 1. Any other material information not involving commercial secrets<br> 2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as

Parabolic Drugs Limited has informed the Exchange that Intimation regarding change of IRP and appointment of RP in the matter of Corporate Insolvency Resolution Process (CIRP) Of Parabolic Drugs Limited.

Parabolic Drugs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 29, 2018

Parabolic Drugs Limited has informed the Exchange that the Company has fixed Book Closure from September 23, 2018 to September 29, 2018 for the purpose of Annual General Meeting

Parabolic Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 29, 2018

Parabolic Drugs Limited has informed the Exchange that Corporate insolvency process has been commenced against the Company as per order dated August 23, 2018 & August 30, 2018, passed by honorable National Company Law Tribunal, Chandigarh Bench, Chandigarh under the Insolvency & Bankruptcy Code, 2016 in CP (IB) No.102/Chd/CHD/2018 in the case of M/s. Weather Makers Pvt. Ltd. Vs. M/s. Parabolic Drugs Limited. Mr. Sanjay Kumar Aggarwal, having Registration No.IBBI/IPA-002/IP-N00126/2017-18/10295 was appointed as an Interim Resolution Profession.

PARABDRUGS:The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 14-Aug-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Board meeting held on August 14, 2018.".On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);<br>The response of the Company is attached.

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 14-Aug-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Board meeting held on August 14, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);<br> The response of the Company is awaited.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended June 30, 2018.

Parabolic Drugs Limited has informed the Exchange regarding Board meeting held on August 14, 2018.

Parabolic Drugs Limited has informed the Exchange regarding change in Corporate Office of the company from S.C.O. 99-100, level third and fourth, Sector 17-B, Chandigarh to S.C.O. 186-187, 2nd floor, Sector 8C, Chandigarh.

Parabolic Drugs Limited has informed the Exchange regarding change in Registered Office of the company.from S.C.O. 99-100, level third and fourth, Sector 17-B, Chandigarh to S.C.O. 186-187, 2nd floor, Sector 8C, Chandigarh.

Parabolic Drugs Limited has informed the Exchange regarding Board meeting held on July 21, 2018.1. Considered and approved the change of registered/Corporate office of the company from S.C.O. 99-100, level third and fourth, Sector 17-B, Chandigarh to S.C.O. 186-187, 2nd floor, Sector 8C, Chandigarh.

The Exchange had sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted -2. Standalone Reconciliation of Equity not submitted -3. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -4. Consolidated Reconciliation of profit and los

The Exchange has sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted -2. Standalone Reconciliation of Equity not submitted -3. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -4. Consolidated Reconciliation of profit and loss

PARABDRUGS:The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 29-May-2018, regarding regarding Board meeting held on May 29, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is attached.

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 29-May-2018, regarding regarding Board meeting held on May 29, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2018.

Parabolic Drugs Limited has informed the Exchange regarding Board meeting held on May 29, 2018.

Parabolic Drugs Limited and Promoter has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 13-Feb-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on February 13, 2018.This is to inform you that the Board of Directors in its Meeting held on 13th February, 2018 and concluded at 05:10 p.m. :1. Approved the Unaudited Financial Results of the Company for the Quarter ended on 31st December, 2017.2. This is to inform you that Mr. Ashok Kumar Jindal, Chief Financial Officer and Compliance Officer of the Company has resig

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 13-Feb-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on February 13, 2018.This is to inform you that the Board of Directors in its Meeting held on 13th February, 2018 and concluded at 05:10 p.m. :1. Approved the Unaudited Financial Results of the Company for the Quarter ended on 31st December, 2017.2. This is to inform you that Mr. Ashok Kumar Jindal, Chief Financial Officer and Compliance Officer of the

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2017.

Parabolic Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on February 13, 2018.This is to inform you that the Board of Directors in its Meeting held on 13th February, 2018 and concluded at 05:10 p.m. :1. Approved the Unaudited Financial Results of the Company for the Quarter ended on 31st December, 2017.2. This is to inform you that Mr. Ashok Kumar Jindal, Chief Financial Officer and Compliance Officer of the Company has resigned from the service of the Company to pursue future career objectives.3. The Company is in the process of appointing a C

PARABDRUGS:The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 20-Dec-2017, regarding Outcome of Board Meeting held on December 20, 2017.This is to inform you that the Board of Directors in its Meeting held on 20th December, 2017 and concluded at 03:15 p.m. : 1. This is to inform you that Ms. Ishrat Gill, Company Secretary and Compliance Officer of the Company has resigned from the service of the Company to pursue future career objectives.1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is enclo

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 20-Dec-2017, regarding Outcome of Board Meeting held on December 20, 2017.This is to inform you that the Board of Directors in its Meeting held on 20th December, 2017 and concluded at 03:15 p.m. : 1. This is to inform you that Ms. Ishrat Gill, Company Secretary and Compliance Officer of the Company has resigned from the service of the Company to pursue future career objectives.1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is await

Parabolic Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on December 20, 2017.This is to inform you that the Board of Directors in its Meeting held on 20th December, 2017 and concluded at 03:15 p.m. :1. This is to inform you that Ms. Ishrat Gill, Company Secretary and Compliance Officer of the Company has resigned from the service of the Company to pursue future career objectives.2. The Company is in the process of appointing a Company Secretary who will act as the Compliance Officer of the Company. In the meantime, Mr. Ashok Kumar Jindal (Chief F

The Exchange had sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Reconciliation of profit and loss not submitted -2. Reconciliation of Equity not submitted The response of the Company is enclosed.

The Exchange has sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Reconciliation of profit and loss not submitted -2. Reconciliation of Equity not submitted The response of the Company is awaited.

Parabolic Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on November 13, 2017.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended 30-Sep-2017.

Significant increase in price has been observed in Parabolic Drugs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Parabolic Drugs Limited has submitted their response.

Significant increase in price has been observed in Parabolic Drugs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

Parabolic Drugs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 29, 2017. Further, the company has informed the Exchange regarding voting results.

This is to bring to your kind notice that pursuant to Regulation 30 of SEBI (Listing Obligations abd Disclosure Requirements) Regulations, 2015 we enclose herewith summary proceedings of the 21st Annual General Meeting of the Company held on 29th September, 2017 at PHD House, Sector 31-A, Chandigarh. Kindly take the above information on your record and oblige.

Parabolic Drugs Limited has informed the Exchange regarding 'This is to bring to your kind notice that pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we enclose herewith summary proceedings of the 21st Annual General Meeting of the Company held on 29th September, 2017 at PHD House, Sector 31-A, Chandigarh. Kindly take the above information on your record and oblige.'.

Parabolic Drugs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 29, 2017

Parabolic Drugs Limited has informed the Exchange regarding Change in Auditors of the company.Pursuant to Section 139 of Companies Act, 2013 and Rules made thereunder, it is mandatory for the Company to rotate the Statutory Auditor on completion of maximum term permitted under the said Section. Accordingly, based on the recommendation of the Board of Directors and Audit Committee of the Company, the members of the Company in their 21st Annual General Meeting held on 29th September, 2017 appointed V.K. Jindal & Associates, Chartered Accountants as Statutory Auditors of the

The Exchange had sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.On basis of above the Company was required to clarify the following: -1. Reconciliation of profit and loss not submitted. -2. Financial results not submitted as per Ind-AS format. -3. Financial results not submitted as per Schedule III to the Companies Act, 2013The response of the Company is enclosed.

Parabolic Drugs Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from September 23, 2017 to September 29, 2017 (both days inclusive) for the purpose of Annual General Meeting.

Parabolic Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 29, 2017